Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • moubied65 moubied65 Oct 27, 2011 5:15 PM Flag

    This 100 dollor stock.

    Read what they said in thier report.
    Vertex also today provided an update on ongoing and planned clinical trials for its broad pipeline of potential new treatments for hepatitis C, cystic fibrosis, rheumatoid arthritis, epilepsy and influenza. In addition to INCIVEK, Vertex has seven other potential medicines in clinical development

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yes it might be. I am very interested to see what our friendly market makers do to this stock tomorrow during the day. This stock is now so fundamentally undervalued that it's almost ridiculous.

      • 1 Reply to greymattermatters
      • Totally agree about being undervalued at this point. We need to get rid of analysts like Adam Feuerstein and The Street.com with comments such as the one below with potentially stronger Hep C drugs
        coming closer to approval. Closer being most
        likely 2 years down the road. Gives us all a
        break Adam and take a more realistic look at the whole picture. VRTX is currently the Secretariat of Hep C with an excellent pipeline of new drugs. I'll stay long VRTX and you can buy JNJ, VRUS and ABT. I'll be waiting for you at the finish line.


        Analysts expect a lot from Incivek: $793 million in 2011 sales jumping to $2 billion in 2012, according to an average of analyst estimates compiled by but not endorsed by Vertex.

        Incivek competes against Merck's(MRK_) Victrelis today but newer, potentially stronger hepatitis C drugs from Johnson & Johnson(JNJ_), Pharmasset(VRUS_) and Abbott(ABT_), among others, are moving closer to approval.

 
VRTX
133.19-0.56(-0.42%)3:25 PMEDT